(IVIG) to current therapy. IVIG should not be used routinely to treat GPA/MPA but can be considered at certain treatment doses (e.g., 2 gm/kg) as adjunctive therapy for short-term control, while waiting for remission induction therapy (i.e., rituximab or cyclophosphamide) to become effective (see above recommendation) Treatment of sinonasal, airway, and mass lesions Ungraded position statement: For patients with sinonasal involvement in GPA, nasal rinses and topical nasal therapies